Jaguar Health's revenue for the
three
months ended in Mar. 2024 was €2.16 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €9.38 Mil.
Jaguar Health's Revenue per Share for the
three
months ended in Mar. 2024 was €0.82.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €15.25.
Warning Sign:
Jaguar Health Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Jaguar Health was -96.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -79.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 11 years, Jaguar Health's highest 3-Year average Revenue per Share Growth Rate was -54.50% per year. The lowest was -79.90% per year. And the median was -67.20% per year.
Jaguar Health Revenue Historical Data
The historical data trend for Jaguar Health's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jaguar Health's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jaguar Health's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jaguar Health's Revenue distribution charts can be found below:
* The bar in red indicates where Jaguar Health's Revenue falls into.
Jaguar Health Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €9.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jaguar Health (HAM:1JA) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Jaguar Health Revenue Related Terms
Thank you for viewing the detailed overview of Jaguar Health's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments-human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HAM:1JA has been successfully added to your 